Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dublin, April 15, 2026 (GLOBE NEWSWIRE) -- The "Pharmacovigilance Aspects of Licensing Agreements (June 25, 2026)" training has been added to ResearchAndMarkets.com's offering.This intensive...
-
First Olmsted syndrome patient dosed in global Phase 1b study Company now operating under its new name, Orvida Pharma NESS ZIONA, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Orvida Pharma (formerly...
-
Tokyo, Japan and Cambridge, UK, 15 April 2026 – Nxera Pharma Co. Ltd (“Nxera” or the “Company”; TSE 4565) announces that, in connection with the introduction of the Employee Stock Ownership Plan for...
-
Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026QUVIVIQ® is approved through Taiwan’s...
-
NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with...
-
Idorsia thanks Alberto Gimona – most recently Head of Global Clinical Development and Medical Affairs – and wishes him all the best for a well-deserved retirementAmer Joseph joins Idorsia as EVP,...
-
Tokyo, Japan and Cambridge, UK, 09 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a second development milestone under its multi-target...
-
LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
-
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no...
-
VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse...